European Commission approves Opdivo plus Cambometyx for advanced kidney cancer
Checkpoint inhibitor plus tyrosine kinase inhibitor approved for the first-line treatment of advanced renal cell carcinoma
The European Commission (EC) has approved a combination of Bristol Myers Squibb’s (BMS) Opdivo with Ipsen’s Cabometyx for the first-line treatment of advanced renal cell carcinoma (RCC) – the most common form of kidney cancer.
BMS’ checkpoint inhibitor Opdivo (nivolumab) is already approved in combination with CTLA-4 inhibitor Yervoy (ipilimumab) as an initial treatment for advanced RCC patients.
The EC approval for Opdivo plus tyrosine kinase inhibitor Cabometyx (cabozantinib) is based on results from the phase 3 CheckMate-9ER trial, which compared BMS/Ipsen’s regimen to Pfizer’s older TKI Sutent (sunitinib) in patients with advanced RCC.
New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer
Data presented at the virtual American Society of Clinical Oncology’s Genitourinary Cancers Symposium
New data for Merck & Co (MSD) and Eisai’s Keytruda plus Lenvima combination treatment has demonstrated further promise for the therapy in advanced renal cell carcinoma (RCC) – the most common form of kidney cancer in adults.
The new investigational data, revealed at the virtual American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU), comes from the phase 3 KEYNOTE-581/CLEAR study.
In this study, checkpoint inhibitor Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and Lenvima plus everolimus were compared to Pfizer’s tyrosine kinase inhibitor (TKI) Sutent (sunitinib) for the first-line treatment of patients with advanced RCC.
BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer
Combination also demonstrated benefit in sarcomatoid subgroup with poor prognoses
Bristol Myers Squibb (BMS) and Exelixis have revealed new analyses from a phase 3 study of their Opdivo and Cabometyx combination in kidney cancer.
The updated results come from the phase 3 CheckMate-9ER trial, which compared BMS’ checkpoint inhibitor Opdivo (nivolumab) and Exelixis’ tyrosine kinase inhibitor (TKI) Cabometyx to Pfizer’s older drug Sutent (sunitinib) in the first-line treatment of advanced renal cell carcinoma (RCC) – the most common type of kidney cancer in adults.
After a median follow-up of two years, the Opdivo/Cabometyx combination continued to demonstrate superior progression-free survival (PFS), objective response rate (ORR) and overall survival (OS) compared to Sutent.
Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer
Combination treatment topped Pfizer s Sutent in phase 3
Merck & Co/MSD and Eisai’s Keytruda plus Lenvima combination has scored positive top-line results from a phase 3 trial in advanced renal cell carcinoma (a form of kidney cancer).
The results, from the KEYNOTE-581/CLEAR trial, demonstrated that Keytruda (pembrolizumab) and Lenvima (lenvatinib) met the primary endpoint of improved progression-free survival (PFS) compared to Pfizer’s Sutent (sunitinib) in first-line advanced renal cell carcinoma (RCC) patients.
The combination treatment also met key secondary endpoints of overall survival (OS) and objective response rate (ORR).